Robert Brown Biography and Net Worth



Rob Brown joins Brickell as Chief Executive Officer, after having spent over 30 years at Eli Lilly and Company, where he most recently served as chief marketing officer (CMO) and senior vice president of marketing from 2009 through 2018. As CMO, Brown was responsible for building and leading marketing capabilities across Lilly’s pharmaceutical business units, including diabetes, oncology, emerging markets and Lilly Bio-Medicines.
Prior to his role as CMO, Brown held the position of vice president and chief marketing officer for Lilly USA from 2007 - 2009, where he partnered with the business units to ensure Lilly continued to develop industry leading marketing capabilities, streamline and improve marketing processes, and transform marketing by building a consumer marketing center of excellence.

From 2003-2007, Brown was the executive director of marketing for the Intercontinental region, including responsibility for Europe. As the head marketer for Lilly’s international operations, Brown was responsible for the marketing of all Lilly products outside the United States.

Brown previously served as the global marketing director for Cialis and Lilly ICOS, a 50/50 joint venture between Lilly and ICOS Corp from 1999-2003. Brown oversaw the global marketing strategy for the first competitor to Viagra and influenced the product development to ensure maximum market value. In 2004, Cialis was awarded Best Brand Launch of the Year by the Pharmaceutical Marketing Congress.

In addition, Brown held a variety of other leadership roles of increasing responsibility within Lilly’s sales, marketing and product management departments, including serving as general manager for Lilly China, where he helped Lilly establish its presence. During his tenure as GM, he managed a joint venture in Suzhou, oversaw the construction of Lilly’s first manufacturing facility and expanded the affiliate’s reach from 12 to 45 cities. Notably, Brown also helped establish STC Corporation, a generic subsidiary for Lilly, and served as its first president.

Brown joined Lilly in 1985, after receiving a bachelor’s degree in economics from DePauw University and a master’s in business administration from Indiana University. Brown currently serves on the board of trustees of Franklin College.

What is Robert Busard Brown's net worth?

The estimated net worth of Robert Busard Brown is at least $0.00 as of March 15th, 2021. Mr. Brown owns 186,957 shares of Brickell Biotech stock worth more than $0 as of December 15th. This net worth approximation does not reflect any other investments that Mr. Brown may own. Additionally, Mr. Brown receives a salary of $816,730.00 as CEO at Brickell Biotech. Learn More about Robert Busard Brown's net worth.

How old is Robert Busard Brown?

Mr. Brown is currently 60 years old. There are 6 older executives and no younger executives at Brickell Biotech. Learn More on Robert Busard Brown's age.

What is Robert Busard Brown's salary?

As the CEO of Brickell Biotech, Inc., Mr. Brown earns $816,730.00 per year. Learn More on Robert Busard Brown's salary.

How do I contact Robert Busard Brown?

The corporate mailing address for Mr. Brown and other Brickell Biotech executives is 5777 CENTRAL AVENUE SUITE 102, BOULDER CO, 80301. Brickell Biotech can also be reached via phone at (720) 505-4755 and via email at [email protected]. Learn More on Robert Busard Brown's contact information.

Has Robert Busard Brown been buying or selling shares of Brickell Biotech?

Robert Busard Brown has not been actively trading shares of Brickell Biotech during the last quarter. Most recently, on Monday, March 15th, Robert Busard Brown bought 100,000 shares of Brickell Biotech stock. The stock was acquired at an average cost of $1.18 per share, with a total value of $118,000.00. Following the completion of the transaction, the chief executive officer now directly owns 186,957 shares of the company's stock, valued at $220,609.26. Learn More on Robert Busard Brown's trading history.

Who are Brickell Biotech's active insiders?

Brickell Biotech's insider roster includes Robert Brown (CEO), Deepak Chadha (Insider), Reginald Hardy (Chairman), David McAvoy (General Counsel), and Andrew Sklawer (COO). Learn More on Brickell Biotech's active insiders.

Robert Busard Brown Insider Trading History at Brickell Biotech

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/15/2021Buy100,000$1.18$118,000.00186,957View SEC Filing Icon  
See Full Table

Robert Busard Brown Buying and Selling Activity at Brickell Biotech

This chart shows Robert Busard Brown's buying and selling at Brickell Biotech by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Brickell Biotech Company Overview

Brickell Biotech logo
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.86
Low: $0.77
High: $0.93

2 Week Range

Now: N/A

Volume

31,300 shs

Average Volume

206,730 shs

Market Capitalization

$6.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.02